Boehringer, Lilly launch type 2 diabetes game

Boehringer Ingelheim and Eli Lilly & Company have launched an educational digital game for type 2 diabetes patients called Complications Combat.

The game is designed to raise awareness of the many complications associated with type 2 diabetes and the challenges both physicians and patients face when considering and managing these on a daily basis. The game is available in both PC and iPad formats.

Users can effectively manage type 2 diabetes and its complications by “clicking or swiping the complications and ‘friends’, which are the healthy steps for managing the condition, to the correct side of the screen to maintain optimal patient health for as long as possible”.

“The aim and design of the game is simple. However, effective management of type 2 diabetes and its complications is not. To simulate this, players are tasked with simultaneously saving the healthy lifestyle items whilst combating the many complications – and it is not easy.”

Arnd Prilipp, Launch and Established Products CVM Boehringer Ingelheim.

Diabetes is a chronic disease that occurs when the body doesn’t properly produce, or use, the hormone insulin. It affects an estimated 371 million people worldwide, with type 2 diabetes accounting for 90% of these cases.

Uncontrolled type 2 diabetes can lead to hyperglycaemia which, if untreated in the long-term, can cause series medical complications in all parts of the body, such as stroke, kidney disease and eye problems.

This isn’t Boehringer’s first educational game – back in September 2012, the pharma company launched a beta version of its social media game, Syrum

Boehringer and Lilly began their diabetes alliance in January 2011; focusing on three pipeline compounds; including linagliptin. In the United States; linagliptin is marketed as Tradjenta.



Related news:

Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, “Complications Combat” (Reuters)

Reference links:

Boehringer Ingelheim press release

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.